<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00369395</url>
  </required_header>
  <id_info>
    <org_study_id>206-MM-201</org_study_id>
    <nct_id>NCT00369395</nct_id>
  </id_info>
  <brief_title>A Study of Volociximab in Metastatic Melanoma</brief_title>
  <official_title>A Phase 2, Open-Label, Two-Stage Study of Volociximab (M200) for the Treatment of Subjects With Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, multicenter, research study determining the effects of an investigational&#xD;
      drug called volociximab in metastatic melanoma.&#xD;
&#xD;
      The purpose of the study is to compare the clinical benefit and safety of volociximab.&#xD;
      Pharmacokinetics and mechanism of action will also be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient clinical activity&#xD;
  </why_stopped>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS) rate at the Week 8 visit, defined as the number of subjects who have not progressed by the Week 8 visit</measure>
    <time_frame>8 weeks intervals</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of volociximab</measure>
    <time_frame>Every infusion and follow up visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess safety by recording and evaluating adverse events (AEs); changes in vital signs, hematology, blood chemistry, and urinalysis parameters; and anti-volociximab antibody formation</measure>
    <time_frame>Throught study and follow up period,approx. 15 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Stage IV Melanoma</condition>
  <arm_group>
    <arm_group_label>Volociximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volociximab 15 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>volociximab</intervention_name>
    <description>Volociximab, 15 mg/kg, IV infusion once a week for 8 weeks. Subjects who achieved SD or better at Day 50 Â± 2 days (Week 8) were eligible to continue receiving weekly infusions of volociximab until disease progression.</description>
    <arm_group_label>Volociximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Must give written informed consent and any authorizations required by local law (e.g.,&#xD;
             Protected Health Information [PHI]).&#xD;
&#xD;
          2. Aged &gt;=18 years old at the time of informed consent.&#xD;
&#xD;
          3. Stage III and Stage IV unresectable melanoma with documented progression during or&#xD;
             following the most recent prior melanoma therapy.&#xD;
&#xD;
          4. Must have failed at least 1 prior therapy for metastatic disease.&#xD;
&#xD;
          5. Must have at least 2 cutaneous, subcutaneous, or nodal metastases that are safely&#xD;
             accessible for pre treatment and post treatment biopsies.&#xD;
&#xD;
          6. Must agree to pre-treatment and post-treatment biopsies of tumor lesions (subjects in&#xD;
             Stage 1 only).&#xD;
&#xD;
          7. Must have at least 1 measurable target lesion for CT/MRI assessment, according to&#xD;
             RECIST criteria.&#xD;
&#xD;
          8. ECOG Performance Status &lt;=1.&#xD;
&#xD;
          9. Acceptable laboratory results&#xD;
&#xD;
         10. Life expectancy &gt;=12 weeks.&#xD;
&#xD;
         11. Male subjects and female subjects of child bearing potential must be willing to&#xD;
             practice effective contraception during the study and be willing and able to continue&#xD;
             contraception for 4 months after last infusion of study treatment.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Subjects with any other active malignancy in addition to metastatic melanoma.&#xD;
&#xD;
          2. CNS metastases, unless stable for at least 2 months following definitive local therapy&#xD;
             (surgery, stereotactic radiation). Subjects may not require treatment with steroids or&#xD;
             anticonvulsants.&#xD;
&#xD;
          3. History of any other significant medical condition, including cardiovascular,&#xD;
             pulmonary, neurologic, or autoimmune disease; active infections (e.g., bacterial or&#xD;
             fungal); or a psychiatric condition within 6 months of Day 1&#xD;
&#xD;
          4. History of hepatitis B or C.&#xD;
&#xD;
          5. Known history of HIV infection or AIDS.&#xD;
&#xD;
          6. History of thromboembolic or cerebrovascular events, such as stroke, transient&#xD;
             ischemic attack, deep vein thrombosis, or bleeding disorders within 12 months prior to&#xD;
             Day 1.&#xD;
&#xD;
          7. Prior radiation therapy, chemotherapy, hormonal therapy, or immunotherapy for melanoma&#xD;
             within 4 weeks prior to Day 1.&#xD;
&#xD;
          8. Previous exposure to volociximab.&#xD;
&#xD;
          9. Aspirin, high dose warfarin, or heparin use. (Note: Aspirin &lt;=81 mg/day, low-dose&#xD;
             warfarin 1 mg/day or low-dose heparin for IV catheter patency is allowed.)&#xD;
&#xD;
         10. Major surgery within 4 weeks prior to Day 1.&#xD;
&#xD;
         11. Requirement for immunosuppression, and/or systemic steroid therapy.&#xD;
&#xD;
         12. Investigational therapies within 4 weeks prior to Day 1 or 4 half lives of the prior&#xD;
             investigational drug (whichever is longer).&#xD;
&#xD;
         13. Known hypersensitivity to murine or chimeric antibodies.&#xD;
&#xD;
         14. Any condition that, in the opinion of the Investigator, makes the subject unsuitable&#xD;
             for study participation.&#xD;
&#xD;
         15. Female subjects who are pregnant or currently breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mihail Obrocea, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 70357</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 70356</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 70375</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 70376</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 70359</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 70380</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 70377</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>August 24, 2006</study_first_submitted>
  <study_first_submitted_qc>August 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2006</study_first_posted>
  <last_update_submitted>April 25, 2012</last_update_submitted>
  <last_update_submitted_qc>April 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>melanoma</keyword>
  <keyword>antibody</keyword>
  <keyword>angiogenesis</keyword>
  <keyword>volociximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Volociximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

